0000950170-24-108577.txt : 20240920
0000950170-24-108577.hdr.sgml : 20240920
20240920212152
ACCESSION NUMBER: 0000950170-24-108577
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240920
FILED AS OF DATE: 20240920
DATE AS OF CHANGE: 20240920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SINGLETON J MATTHEW
CENTRAL INDEX KEY: 0001243514
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 241314492
MAIL ADDRESS:
STREET 1: 286 STANWICH ROAD
CITY: GREENWICH
STATE: CT
ZIP: 06830
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-09-20
0001607678
Viking Therapeutics, Inc.
VKTX
0001243514
SINGLETON J MATTHEW
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
true
false
false
false
true
Common Stock, par value $0.00001 per share
2024-09-20
4
M
false
10300
1.19
A
19800
D
Common Stock, par value $0.00001 per share
2024-09-20
4
S
false
10300
69.50
D
9500
D
Stock Option (Right to Buy)
1.19
2024-09-20
4
M
false
10300
0
D
2018-01-03
2027-01-03
Common Stock
10300
0
D
The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person.
/s/ Michael Morneau, as Attorney-in-Fact
2024-09-20